je.st
news
Tag: or
Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting
2015-11-15 01:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Language: English Contact: MerckMedia:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
New Vizio hack reveals company shares your data whether you accept its privacy policy or not
2015-11-12 13:30:13| Extremetech
New data on Vizio Smart TV's indicates that they've been sending your personal viewing habits to third parties whether you agreed to their terms of service or not. The problem should be fixed in the latest software update.
Whats Going on in Antartica? Is the Ice Melting or Growing?
2015-11-10 15:38:00| Climate Ark Climate Change & Global Warming Newsfeed
EcoWatch: Last week a study was published in the Journal of Glaciology by a group of NASA researchers reporting that satellite data shows that, as a whole, Antarctica has been gaining--rather than losing--ice mass during the past two or more decades. So was NASA and the Intergovernmental Panel on Climate Change (IPCC) wrong about Antarcticas ice loss? Is the Antarctic ice growing? The short answer is best summarized by the title of Andrew Freedmans article on Mashable (which everyone should read):...
Merck Statement on FDA Advisory Committee Meeting for BRIDION (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium
2015-11-06 20:13:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss BRIDION (sugammadex). BRIDION is the proposed trade name for Mercks investigational agent for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Doris Li, 908-740-1903orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: or
statement
agent
meeting
Oregonian: Multnomah County takes first step in Burnside Bridge retrofit or replacement
2015-11-06 15:54:06| PortlandOnline
News story posted to oregonlive.com November 5, 2015.
Sites : [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] next »